This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Envista (NVST) Q2 Earnings & Revenues Miss, Margins Fall
by Zacks Equity Research
Envista's (NVST) Spark division sales witness a slowdown in the second quarter due to the deferment of a larger portion of case revenues.
Here's What Key Metrics Tell Us About Envista (NVST) Q2 Earnings
by Zacks Equity Research
Although the revenue and EPS for Envista (NVST) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Envista (NVST) Q2 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Envista (NVST) delivered earnings and revenue surprises of -59.26% and 2.30%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Wall Street's Insights Into Key Metrics Ahead of Envista (NVST) Q2 Earnings
by Zacks Equity Research
Get a deeper insight into the potential performance of Envista (NVST) for the quarter ended June 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Canopy Growth Corporation (CGC) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Canopy Growth (CGC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Envista (NVST) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Envista (NVST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Envista (NVST) Down 4.7% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Envista (NVST) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Envista (NVST) Q1 Earnings Miss Estimates, Margins Down
by Zacks Equity Research
Envista (NVST) registers a year-over-year decline in both segments in the first quarter of 2024.
Here's What Key Metrics Tell Us About Envista (NVST) Q1 Earnings
by Zacks Equity Research
The headline numbers for Envista (NVST) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Envista (NVST) Lags Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Envista (NVST) delivered earnings and revenue surprises of -16.13% and 0.87%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Envista (NVST) Faces Macroeconomic Challenges, FX Headwind
by Zacks Equity Research
The challenging macroeconomic conditions are resulting in a significant escalation in Envista's (NVST) costs and expenses.
Envista (NVST) Down 5.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Envista (NVST) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Envista (NVST) Q4 Earnings Miss Estimates, Margins Down
by Zacks Equity Research
Strong performance in the Speciality Products & Technologies segment contributes to Envista's (NVST) Q4 revenues.
Envista (NVST) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
Although the revenue and EPS for Envista (NVST) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Medical Products Stocks' Earnings Due on Feb 7: STE, PAHC & NVST
by Urmimala Biswas
Medical Products companies' quarterly results are likely to reflect a year-over-year decline in earnings. Let's see how STE, PAHC and NVST fare this time.
Curious about Envista (NVST) Q4 Performance? Explore Wall Street Estimates for Key Metrics
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for Envista (NVST), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2023.
Haemonetics (HAE) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Haemonetics (HAE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Envista (NVST) Q4 Earnings Expected to Decline
by Zacks Equity Research
Envista (NVST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for December 21st
by Zacks Equity Research
DSKE, NVST and HENKY have been added to the Zacks Rank #5 (Strong Sell) List on December 21, 2023.
Envista (NVST) Up 6.8% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Envista (NVST) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Envista (NVST) Q3 Earnings Miss Estimates, Gross Margin Down
by Zacks Equity Research
Envista's (NVST) Q3 performance is impacted by the negative impact of Russia and the weakness of higher-end specialty procedures in developed markets.
Compared to Estimates, Envista (NVST) Q3 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for Envista (NVST) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
MedTech Stocks' Q3 Earnings Due on Nov 1: IDXX, EXAS & More
by Urmimala Biswas
MedTech companies' third-quarter results are likely to reflect a year-over-year decline. Let's see how IDXX, EXAS, TNDM and NVST fare this time.
Select Medical (SEM) Q2 Earnings Meet, Revenues Rise Y/Y
by Zacks Equity Research
Select Medical's (SEM) Q2 results reflect solid segmental revenues, attributable to higher patient days and outpatient visits. Management projects adjusted EPS of $1.86-$2.03 for 2023.
Envista (NVST) Q2 Earnings Top Estimates, Margins Expands
by Zacks Equity Research
Consistent growth in the Specialty Products & Technologies segment and a return to growth in the Equipment & Consumables segment drive Envista's (NVST) Q2 revenues.